Ligand Pharmaceuticals (LGND) Scheduled to Post Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.75 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.34. Ligand Pharmaceuticals had a return on equity of 7.91% and a net margin of 29.69%. The business had revenue of $41.50 million for the quarter, compared to analyst estimates of $33.04 million. During the same period last year, the company earned $1.10 EPS. Ligand Pharmaceuticals’s revenue for the quarter was up 57.2% compared to the same quarter last year. On average, analysts expect Ligand Pharmaceuticals to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock opened at $110.22 on Tuesday. The company has a market capitalization of $2.01 billion, a P/E ratio of 51.03 and a beta of 0.99. Ligand Pharmaceuticals has a fifty-two week low of $51.21 and a fifty-two week high of $115.53. The stock has a 50 day moving average price of $104.48 and a two-hundred day moving average price of $94.18.

Insiders Place Their Bets

In other news, insider Andrew Reardon sold 1,500 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $106.39, for a total value of $159,585.00. Following the completion of the transaction, the insider now owns 22,534 shares of the company’s stock, valued at approximately $2,397,392.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Andrew Reardon sold 1,500 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $106.39, for a total transaction of $159,585.00. Following the sale, the insider now owns 22,534 shares in the company, valued at approximately $2,397,392.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Matthew E. Korenberg sold 18,245 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $98.50, for a total transaction of $1,797,132.50. Following the completion of the sale, the chief operating officer now directly owns 68,368 shares in the company, valued at $6,734,248. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,613 shares of company stock worth $5,255,692. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on LGND. HC Wainwright reiterated a “buy” rating and set a $157.00 price target on shares of Ligand Pharmaceuticals in a report on Thursday, October 31st. Craig Hallum raised their target price on Ligand Pharmaceuticals from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Benchmark boosted their price target on Ligand Pharmaceuticals from $95.00 to $110.00 and gave the company a “buy” rating in a report on Monday, August 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $130.00 price objective on shares of Ligand Pharmaceuticals in a report on Wednesday, August 7th. Finally, Barclays boosted their target price on Ligand Pharmaceuticals from $110.00 to $125.00 and gave the company an “overweight” rating in a research note on Monday, October 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $132.83.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.